3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
2
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Motor Activity
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
Bevacizumab
119
Fluorouracil
91
Leucovorin
83
Cetuximab
83
Oxaliplatin
80
pembrolizumab
70
Irinotecan
67
Nivolumab
46
Capecitabine
43
Specimen Handling
40
regorafenib
30
Folfox protocol
29
trifluridine tipiracil drug combination
28
Magnetic Resonance Spectroscopy
27
Biopsy
27
Panitumumab
26
Standard of Care
25
HMPL-013
25
IFL protocol
21
Gemcitabine
20
Blood Specimen Collection
19
atezolizumab
18
Trifluridine
18
Cisplatin
18
tislelizumab
17
balstilimab
16
Colonoscopy
16
Carboplatin
16
encorafenib
15
Paclitaxel
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Geritol
×
1 year
×
Clear all
NCT07341217
2026-01-14
CHEMOBRAIN
Lancaster University
Phase NA
Not yet recruiting
86 enrolled